Date,Articles
2014-06-20,"{""abstract"": ""More health prescription plans are refusing to cover certain drugs unless the companies charge less for them."", ""web_url"": ""https://www.nytimes.com/2014/06/21/business/health-plans-bring-pressure-to-bear-on-drug-prices.html"", ""snippet"": ""More health prescription plans are refusing to cover certain drugs unless the companies charge less for them."", ""lead_paragraph"": ""In dealing with health plans, drug companies are facing a new imperative \u2014 bargain or be banned."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/21/business/jp-prices/jp-prices-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/21/business/jp-prices/jp-prices-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/21/business/jp-prices/jp-prices-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/21/business/jp-prices/jp-prices-superJumbo.jpg"", ""height"": 744, ""width"": 1116, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/21/business/jp-prices/jp-prices-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/21/business/jp-prices/jp-prices-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/21/business/jp-prices/jp-prices-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Health Insurers Pressing Down on Drug Prices"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Health Insurers Are Pushing Back on Drug Prices"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CVS Caremark Corporation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novo Nordisk A/S"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-06-20T18:32:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/02951829-4f1e-51bb-91b8-2aa8545cac00"", ""word_count"": 1399, ""uri"": ""nyt://article/02951829-4f1e-51bb-91b8-2aa8545cac00""}"
2014-06-23,"{""abstract"": ""Shire last week turned down a $46 billion bid from Chicago-based AbbVie, but it may be entertaining a higher offer soon."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/23/shire-said-to-hire-goldman-sachs-as-an-adviser/"", ""snippet"": ""Shire last week turned down a $46 billion bid from Chicago-based AbbVie, but it may be entertaining a higher offer soon."", ""lead_paragraph"": ""Goldman Sachs has been hired by Shire as the London-listed drug maker confronts a takeover offer, according to people briefed on the matter. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""height"": 272, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 272}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-jumbo.jpg"", ""height"": 272, ""width"": 600, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg"", ""height"": 272, ""width"": 600, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/24/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Shire Said to Hire Goldman Sachs as an Adviser"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-06-23T21:25:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1e1a0032-c3e1-5b2e-b583-93b86469f36b"", ""word_count"": 263, ""uri"": ""nyt://article/1e1a0032-c3e1-5b2e-b583-93b86469f36b""}"
2014-06-25,"{""abstract"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/25/abbvie-signals-it-will-continue-to-pursue-irish-drug-maker-shire/"", ""snippet"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""lead_paragraph"": ""Updated, 2:28 p.m. | "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie Signals It Will Continue to Pursue Irish Drug Maker Shire"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Defending Its Offer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gonzalez, Richard"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-06-25T13:06:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab"", ""word_count"": 804, ""uri"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab""}"
2014-07-08,"{""abstract"": ""Shire\u2019s board still has some leverage. For one, there\u2019s AbbVie\u2019s own weakness, because roughly 58 percent of its sales come from one drug, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/08/shire-can-get-higher-bid-from-abbvie/"", ""snippet"": ""Shire\u2019s board still has some leverage. For one, there\u2019s AbbVie\u2019s own weakness, because roughly 58 percent of its sales come from one drug, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""lead_paragraph"": ""Shire can get more from AbbVie. Shire, the London-listed drugmaker, is pondering a fresh, $51 billion unsolicited bid from its American rival. AbbVie claims shareholder support and is offering a hefty premium, but Shire\u2019s board can probably extract one more increase in return for its recommendation."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Shire Can Get Higher Bid From AbbVie"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-07-08T19:02:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack and Robert Cyran"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/88430087-f2ff-5cc9-b766-046f2bccad44"", ""word_count"": 363, ""uri"": ""nyt://article/88430087-f2ff-5cc9-b766-046f2bccad44""}"
2014-07-09,"{""abstract"": ""AbbVie said it had \u201cnot received any written commitments of support\u201d from shareholders of Shire for its latest takeover offer, which AbbVie has raised to about $51 billion."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/09/abbvie-backtracks-on-comments-in-shire-bid/"", ""snippet"": ""AbbVie said it had \u201cnot received any written commitments of support\u201d from shareholders of Shire for its latest takeover offer, which AbbVie has raised to about $51 billion."", ""lead_paragraph"": ""LONDON \u2013 AbbVie on Wednesday retracted statements that shareholders of the Irish drug maker Shire were supportive of AbbVie\u2019s takeover bid."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-articleLarge-v2.png"", ""height"": 176, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-articleLarge-v2.png"", ""xlargewidth"": 600, ""xlargeheight"": 176}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-jumbo-v2.png"", ""height"": 183, ""width"": 623, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-superJumbo-v2.png"", ""height"": 183, ""width"": 623, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-thumbStandard.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/09/business/dbpix-abbvie-ft/dbpix-abbvie-ft-thumbStandard.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""AbbVie Backtracks on Comments in Shire Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gonzalez, Richard"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Chicago (Ill)"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-07-09T09:30:10+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/14a5a88c-aa7e-5a12-a656-acb71a5803c7"", ""word_count"": 426, ""uri"": ""nyt://article/14a5a88c-aa7e-5a12-a656-acb71a5803c7""}"
2014-07-11,"{""abstract"": ""The talks follow AbbVie\u2019s revised offer to pay about $51 billion for Shire, which has its headquarters in Ireland and is listed in London. Shire confirmed the talks on Friday but did not provide details of the discussions."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/11/abbvie-and-shire-officials-meet-to-discuss-merger/"", ""snippet"": ""The talks follow AbbVie\u2019s revised offer to pay about $51 billion for Shire, which has its headquarters in Ireland and is listed in London. Shire confirmed the talks on Friday but did not provide details of the discussions."", ""lead_paragraph"": ""Updated, 2:06 p.m. | "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Drug Makers AbbVie and Shire Officials Meet to Discuss Merger"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Chicago (Ill)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""London (England)"", ""rank"": 11, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""New York City"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2014-07-11T17:08:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9facf05b-9f02-5c1a-a05c-565ddced473c"", ""word_count"": 465, ""uri"": ""nyt://article/9facf05b-9f02-5c1a-a05c-565ddced473c""}"
2014-07-14,"{""abstract"": ""Playing hard to get may simply have been a calculated bet by Susan Kilsby, Shire\u2019s board chairwoman and a veteran deal maker at Credit Suisse for many years."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/14/abbvies-bid-played-into-hands-of-shire-boards-merger-expert/"", ""snippet"": ""Playing hard to get may simply have been a calculated bet by Susan Kilsby, Shire\u2019s board chairwoman and a veteran deal maker at Credit Suisse for many years."", ""lead_paragraph"": ""When AbbVie\u2019s overtures for the Dublin-based drug company Shire were first announced last month, The Guardian newspaper in Britain declared in a headline: \u201cShire Chairwoman Susan Kilsby: mergers expert now resists one.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-articleLarge.jpg"", ""height"": 537, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 537}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-jumbo.jpg"", ""height"": 917, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-superJumbo.jpg"", ""height"": 1676, ""width"": 1871, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/14/business/dbpix-drug-shire-kilsby/dbpix-drug-shire-kilsby-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie\u2019s Bid Played Into Hands of Shire Board\u2019s Merger Expert"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kilsby, Susan"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-07-14T16:27:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Anita Raghavan"", ""person"": [{""firstname"": ""Anita"", ""middlename"": null, ""lastname"": ""Raghavan"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3b498358-8200-5110-b9f9-9de3832ff7c1"", ""word_count"": 1493, ""uri"": ""nyt://article/3b498358-8200-5110-b9f9-9de3832ff7c1""}"
2014-07-15,"{""abstract"": ""Another company is moving its headquarters to Europe, in part to pay lower taxes. This time, it\u2019s led by the daughter of a United States senator."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/14/reluctantly-patriot-flees-homeland-to-elude-taxes/"", ""snippet"": ""Another company is moving its headquarters to Europe, in part to pay lower taxes. This time, it\u2019s led by the daughter of a United States senator."", ""lead_paragraph"": ""Heather Bresch grew up around politics. Her father is Joe Manchin, the Democratic senator from West Virginia and a former governor. She has heard him say repeatedly, \u201cWe live in the greatest country on Earth,\u201d as he did in countless political advertisements. And it appeared to rub off on her: Ms. Bresch was named a \u201cPatriot of the Year\u201d in 2011 by Esquire magazine for helping to push through the F.D.A. Safety Innovation Act."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Reluctantly, Patriot Flees Homeland for Greener Tax Pastures"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Reluctantly, Patriot Flees Homeland"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bresch, Heather"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-07-15T01:20:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a06f3011-dc72-5312-b54b-e9c262f97311"", ""word_count"": 1098, ""uri"": ""nyt://article/a06f3011-dc72-5312-b54b-e9c262f97311""}"
2014-07-16,"{""abstract"": ""The Obama administration and Congress appear unlikely to take any action to stem the tide of such deals anytime soon."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/16/obama-administration-seeks-end-to-inversion-deals/"", ""snippet"": ""The Obama administration and Congress appear unlikely to take any action to stem the tide of such deals anytime soon."", ""lead_paragraph"": ""Updated, 9:40 p.m. | "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Treasury Urges End to Foreign Tax Flights, but Quick Action Is Unlikely"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Treasury Urges End To Foreign Tax Flights"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2014-07-16T13:30:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2ce472a0-fa40-5691-b8bb-17d2b6696d19"", ""word_count"": 1141, ""uri"": ""nyt://article/2ce472a0-fa40-5691-b8bb-17d2b6696d19""}"
2014-07-17,"{""abstract"": ""The biggest wedding of the year comes as the Treasury and Congress prepare legislation to prevent tax inversions, possibly retroactively. What provision AbbVie has made for that is unclear."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/17/abbvie-set-to-announce-53-billion-shire-deal/"", ""snippet"": ""The biggest wedding of the year comes as the Treasury and Congress prepare legislation to prevent tax inversions, possibly retroactively. What provision AbbVie has made for that is unclear."", ""lead_paragraph"": ""Updated, 8:41 p.m. | The biggest deal of the year is set to be announced on Friday morning, as the pharmaceutical giant AbbVie plans to announce a $53 billion acquisition of Shire, according to people briefed on the matter."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/18/business/Drug/Drug-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/18/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/18/business/Drug/Drug-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/18/business/Drug/Drug-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/18/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/18/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/18/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie-Shire Deal Is Expected, in a Flight to a Lower-Tax Locale"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""AbbVie-Shire Deal Is Expected, in a Flight to a Lower-Tax Locale"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Hatch, Orrin G"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Illinois"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-07-17T19:50:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/80d393ea-dc2d-545c-8b53-6f4dfa4cebbd"", ""word_count"": 887, ""uri"": ""nyt://article/80d393ea-dc2d-545c-8b53-6f4dfa4cebbd""}"
2014-07-18,"{""abstract"": ""AbbVie agreed on Friday to buy the Irish drug maker Shire for around $54 billion. | Alibaba has pushed its I.P.O. to September. | Growth in wealth management bolstered Morgan Stanley\u2019s second-quarter profit. | New York State\u2019s top financial regulator has proposed regulations for virtual currency companies."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/18/morning-agenda-abbvie-wins-deal-for-shire/"", ""snippet"": ""AbbVie agreed on Friday to buy the Irish drug maker Shire for around $54 billion. | Alibaba has pushed its I.P.O. to September. | Growth in wealth management bolstered Morgan Stanley\u2019s second-quarter profit. | New York State\u2019s top financial regula..."", ""lead_paragraph"": "" ABBVIE CLINCHES $54 BILLION DEAL FOR SHIRE | The pharmaceutical giant AbbVie agreed on Friday to buy the Irish drug maker Shire for around $54 billion, the biggest takeover deal so far this year, Mark Scott writes in DealBook. The deal will allow AbbVie, based outside Chicago, to reincorporate in Britain and reduce its tax bill, representing the largest ever inversion as United States companies rush to pursue the financial advantages of moving overseas, even as lawmakers move to crack down on the increasingly popular maneuver."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: AbbVie Wins Deal for Shire"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-07-18T11:24:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7a8785af-e0f5-5620-a0db-b43a6951f75a"", ""word_count"": 1890, ""uri"": ""nyt://article/7a8785af-e0f5-5620-a0db-b43a6951f75a""}"
2014-07-21,"{""abstract"": ""Alibaba\u2019s I.P.O. could be a bonanza for the scions of Chinese leaders. | The market for subprime auto loans is booming. | Dell shareholders\u2019 appraisal efforts hit a snag. | AbbVie has sealed a $54 billion deal for Shire."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/21/morning-agenda-chinese-elite-tied-to-alibaba-i-p-o/"", ""snippet"": ""Alibaba\u2019s I.P.O. could be a bonanza for the scions of Chinese leaders. | The market for subprime auto loans is booming. | Dell shareholders\u2019 appraisal efforts hit a snag. | AbbVie has sealed a $54 billion deal for Shire."", ""lead_paragraph"": ""When the Chinese Internet giant Alibaba Group completed a $7.6 billion deal in 2012 to buy back half of Yahoo\u2019s stake in the company, it raised part of the money by selling shares to select investors, notably China\u2019s sovereign wealth fund and three prominent Chinese investment firms, Michael Forsythe writes in DealBook. What it did not detail was the deep political connections of the investment firms, Boyu Capital, Citic Capital Holdings and CDB Capital, the China Development Bank\u2019s private investment arm."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: Chinese Elite Tied to Alibaba I.P.O."", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-07-21T11:36:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f0e8284b-8321-5a26-a8d9-fac85482d76f"", ""word_count"": 2079, ""uri"": ""nyt://article/f0e8284b-8321-5a26-a8d9-fac85482d76f""}"
2014-07-22,"{""abstract"": ""Lawmakers spoke out against American companies reincorporating abroad, but there was no consensus on how to address the issue."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/22/senate-panel-takes-on-tax-inversions/"", ""snippet"": ""Lawmakers spoke out against American companies reincorporating abroad, but there was no consensus on how to address the issue."", ""lead_paragraph"": ""The chorus of voices on Capitol Hill calling for an end to corporate inversions grew louder on Tuesday as the Senate Finance Committee held a hearing on the issue of American companies reincorporating abroad, and legislators proposed new punitive measures against inverted companies."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Senate Panel Takes On Tax Inversions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Hatch, Orrin G"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Schumer, Charles E"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-07-22T18:04:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fe0a1e8c-0276-5c95-b66e-0ad3d28ba5e3"", ""word_count"": 556, ""uri"": ""nyt://article/fe0a1e8c-0276-5c95-b66e-0ad3d28ba5e3""}"
2014-07-23,"{""abstract"": ""Sales of Sovaldi reached $3.5 billion in the second quarter, testifying to the effectiveness of the drug, which can essentially cure over 80 percent of patients with few side effects."", ""web_url"": ""https://www.nytimes.com/2014/07/24/business/sales-of-hepatitis-c-drug-sovaldi-soar.html"", ""snippet"": ""Sales of Sovaldi reached $3.5 billion in the second quarter, testifying to the effectiveness of the drug, which can essentially cure over 80 percent of patients with few side effects."", ""lead_paragraph"": ""Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, a huge figure that puts it on track to become one of the world\u2019s best-selling medicines but could intensify concerns about society\u2019s ability to pay for it."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-articleLarge.jpg"", ""height"": 910, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 910}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-jumbo.jpg"", ""height"": 1024, ""width"": 675, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-superJumbo.jpg"", ""height"": 1898, ""width"": 1251, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/24/business/Gilead-1406155701326/Gilead-1406155701326-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Gilead\u2019s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Strong Sales of Hepatitis C Drug Put It on Pace to Become a Blockbuster"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-07-23T20:54:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/15384d26-ba47-50b6-8e4e-b8bc6ad35285"", ""word_count"": 978, ""uri"": ""nyt://article/15384d26-ba47-50b6-8e4e-b8bc6ad35285""}"
2014-07-25,"{""abstract"": ""Kenneth C. Griffin, the head of Citadel, has filed for divorce from his wife, Anne Dias Griffin. | President Obama on Thursday called for an end to so-called inversions. | How AbbVie wooed Shire. | A secret in the bank bailout of Cyprus stirs resentment."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/25/morning-agenda-hedge-fund-managers-headed-for-divorce/"", ""snippet"": ""Kenneth C. Griffin, the head of Citadel, has filed for divorce from his wife, Anne Dias Griffin. | President Obama on Thursday called for an end to so-called inversions. | How AbbVie wooed Shire. | A secret in the bank bailout of Cyprus stirs rese..."", ""lead_paragraph"": "" HEDGE FUND MANAGERS HEADED FOR DIVORCE | For a decade, Kenneth C. Griffin and his wife, Anne Dias Griffin, were a financial powerhouse, two hedge fund managers who captivated the Chicago social scene, Michael J. de la Merced and Alexandra Stevenson write in DealBook. But on Wednesday, Mr. Griffin, the head of the $20 billion investment firm Citadel, filed a divorce petition in Cook County, Ill., citing \u201cirreconcilable differences\u201d after 11 years of marriage. Ms. Dias Griffin has fired back publicly, claiming to have been blindsided by the move. Now, the domestic dispute threatens to push the private couple into the spotlight. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: Hedge Fund Managers Headed for Divorce"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gonzalez, Richard"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Griffin, Kenneth C"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kilsby, Susan"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Murdoch, Rupert"", ""rank"": 8, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 9, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Singer, Paul E"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""21st Century Fox"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Citadel Investment Group"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""El Pollo Loco"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Elliott Management Corp"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Engaged Capital LLC"", ""rank"": 15, ""major"": ""N""}], ""pub_date"": ""2014-07-25T11:32:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3738d832-1841-5b2f-bc56-472e739244c6"", ""word_count"": 2011, ""uri"": ""nyt://article/3738d832-1841-5b2f-bc56-472e739244c6""}"
2014-07-29,"{""abstract"": ""The bill, called the No Federal Contracts for Corporate Deserters Act, would withhold government contracts from companies that seek tax relief by moving overseas."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/29/new-legislation-targets-inversions-from-different-angle/"", ""snippet"": ""The bill, called the No Federal Contracts for Corporate Deserters Act, would withhold government contracts from companies that seek tax relief by moving overseas."", ""lead_paragraph"": ""Lawmakers in Washington ratcheted up the pressure on Tuesday on companies seeking tax relief by moving overseas, introducing a bill that would withhold government contracts from companies that undertake so-called inversion deals."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Legislation Targets Inversions From Different Angle"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""DeLauro, Rosa"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Doggett, Lloyd"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Durbin, Richard J"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Carl M"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLIANCE BOOTS"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Walgreen Company"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-07-29T17:09:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ee277dfc-02ec-54e9-81fe-616d4a503c2a"", ""word_count"": 404, ""uri"": ""nyt://article/ee277dfc-02ec-54e9-81fe-616d4a503c2a""}"
2014-08-06,"{""abstract"": ""A backlash against corporate emigration may have affected the drug store chain\u2019s decision, but harder numbers probably mattered more, Kevin Allison of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/08/06/walgreen-may-be-the-exception-to-the-logic-of-inversions/"", ""snippet"": ""A backlash against corporate emigration may have affected the drug store chain\u2019s decision, but harder numbers probably mattered more, Kevin Allison of Reuters Breakingviews writes."", ""lead_paragraph"": ""Walgreen has encountered a limit to the logic of inversions. The drugstore chain will keep flying the American flag even after agreeing to buy the rest of Swiss-based Alliance Boots for about $15 billion. A backlash against corporate emigration may have affected Walgreen\u2019s decision, but harder numbers probably mattered more."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-articleLarge.jpg"", ""height"": 385, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 385}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-jumbo.jpg"", ""height"": 657, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-superJumbo.jpg"", ""height"": 1315, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/07/business/dbpix-walgreen/dbpix-walgreen-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Walgreen May Be the Exception to the Logic of Inversions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLIANCE BOOTS"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Walgreen Company"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Chicago (Ill)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-08-06T20:15:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Kevin Allison"", ""person"": [{""firstname"": ""Kevin"", ""middlename"": null, ""lastname"": ""Allison"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ec6b42de-487b-50b4-b6c0-9f946548e507"", ""word_count"": 384, ""uri"": ""nyt://article/ec6b42de-487b-50b4-b6c0-9f946548e507""}"
2014-08-08,"{""abstract"": ""Cheap credit, lower tax bills and a desire for revenue, more than economic optimism, may be behind this year\u2019s surge in corporate acquisitions."", ""web_url"": ""https://dealbook.nytimes.com/2014/08/07/stampede-of-mergers-could-mean-growth-or-irrationality-ahead/"", ""snippet"": ""Cheap credit, lower tax bills and a desire for revenue, more than economic optimism, may be behind this year\u2019s surge in corporate acquisitions."", ""lead_paragraph"": ""Something big is happening on Wall Street that is making investment bankers richer. It is also supposed to signal better times ahead for the rest of the country."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/08/business/Mergersjp/Mergersjp-articleLarge-v2.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/08/08/business/Mergersjp/Mergersjp-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/08/business/Mergersjp/Mergersjp-jumbo-v2.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/08/business/Mergersjp/Mergersjp-superJumbo-v2.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/08/business/Mergersjp/Mergersjp-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/08/08/business/Mergersjp/Mergersjp-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/08/08/business/Mergersjp/Mergersjp-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Stampede of Mergers Could Mean Growth, or Irrationality, Ahead"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Deemed Safe to Merge"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Economy"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Einhorn, David"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Murdoch, Rupert"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""21st Century Fox"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Comcast Corporation"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Greenlight Capital Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lorillard Tobacco Co"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Reynolds American Inc"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""T-Mobile US Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Cable Inc"", ""rank"": 17, ""major"": ""N""}], ""pub_date"": ""2014-08-08T01:40:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Peter Eavis and David Gelles"", ""person"": [{""firstname"": ""Peter"", ""middlename"": null, ""lastname"": ""Eavis"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/afbf57d4-cdfe-54d4-8708-54c4e2cb5ceb"", ""word_count"": 1147, ""uri"": ""nyt://article/afbf57d4-cdfe-54d4-8708-54c4e2cb5ceb""}"
2014-08-09,"{""abstract"": ""By allowing a telecom company to spin off part of itself into a real estate investment trust, the I.R.S. has opened a window to a way for many corporations to have lower tax bills."", ""web_url"": ""https://www.nytimes.com/2014/08/10/business/a-corporate-tax-break-thats-closer-to-home.html"", ""snippet"": ""By allowing a telecom company to spin off part of itself into a real estate investment trust, the I.R.S. has opened a window to a way for many corporations to have lower tax bills."", ""lead_paragraph"": ""Rage is rising over American corporations that chop their tax bills by acquiring entities in lower-tax countries. Medtronic, AbbVie and Mylan have all announced such plans \u2014 known as inversions \u2014 in recent months. And Walgreen was poised to relocate to Switzerland after it completes its purchase of Alliance Boots, but did an about-face last week in the face of widespread denunciation."", ""print_section"": ""BU"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/19/business/morgenson/morgenson-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2010/04/19/business/morgenson/morgenson-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/19/business/morgenson/morgenson-jumbo-v2.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/19/business/morgenson/morgenson-superJumbo-v2.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/19/business/morgenson/morgenson-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/04/19/business/morgenson/morgenson-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/19/business/morgenson/morgenson-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Corporate Tax Break That\u2019s Closer to Home"", ""kicker"": ""Fair Game"", ""content_kicker"": null, ""print_headline"": ""A Tax Break That\u2019s Closer to Home"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Morgenson, Gretchen"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Windstream Corporation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Real Estate Investment Trusts"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Real Estate (Commercial)"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-08-09T14:20:04+0000"", ""document_type"": ""article"", ""news_desk"": ""NODESK"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Gretchen Morgenson"", ""person"": [{""firstname"": ""Gretchen"", ""middlename"": null, ""lastname"": ""Morgenson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8ce3d4ba-4e85-58bb-ba35-78fc6433637b"", ""word_count"": 993, ""uri"": ""nyt://article/8ce3d4ba-4e85-58bb-ba35-78fc6433637b""}"
2014-09-02,"{""abstract"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/01/public-pension-funds-stay-mum-on-corporate-expats/"", ""snippet"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""lead_paragraph"": ""In the outcry about the recent merger mania to take advantage of the tax avoidance transactions known as inversions, certain key players have been notably silent: public pension funds."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Public Pension Funds Stay Mum on Corporate Expats"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Staying Mum on Corporate Expats"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pensions and Retirement Plans"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Burger King Corp"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tim Hortons"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-02T01:05:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee"", ""word_count"": 1192, ""uri"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee""}"
2014-09-03,"{""abstract"": ""A Google-backed biotech company plans to build a new Bay Area-based facility to research diseases that afflict the elderly, such as neurodegeneration and cancer."", ""web_url"": ""https://bits.blogs.nytimes.com/2014/09/03/googles-anti-aging-company-announces-new-research-facility/"", ""snippet"": ""A Google-backed biotech company plans to build a new Bay Area-based facility to research diseases that afflict the elderly, such as neurodegeneration and cancer."", ""lead_paragraph"": ""In the world according to Google, cars drive themselves, deliveries are dropped off by drones and eyeglasses double as computers. Also, people live forever. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Calico, Google\u2019s Anti-Aging Company, Announces New Research Facility"", ""kicker"": ""Bits"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Elderly"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levinson, Arthur D"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Calico (California Life Company)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Google Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Francisco Bay Area (Calif)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-09-03T19:03:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Technology"", ""byline"": {""original"": ""By Conor Dougherty"", ""person"": [{""firstname"": ""Conor"", ""middlename"": null, ""lastname"": ""Dougherty"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a2b2b392-0735-58f6-b225-75be5aa5ac1e"", ""word_count"": 441, ""uri"": ""nyt://article/a2b2b392-0735-58f6-b225-75be5aa5ac1e""}"
2014-09-23,"{""abstract"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/23/u-s-curbs-on-inversions-may-deter-some-pharmaceutical-deals/"", ""snippet"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""lead_paragraph"": ""The clampdown by the United States on tax-driven cross-border mergers and acquisitions should deter half-baked pharmaceutical deals. Some American-led transactions, like AbbVie\u2019s recent agreement to buy its British rival Shire, may survive on strategic logic. But pure tax-avoiding combinations look tricky."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 382, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 382}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 653, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 1305, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Curbs on Inversions May Deter Some Pharmaceutical Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-23T19:16:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack and Robert Cyran"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e"", ""word_count"": 383, ""uri"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e""}"
2014-10-15,"{""abstract"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/15/abbvies-u-turn-shows-shire-deal-was-driven-by-taxes/"", ""snippet"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""lead_paragraph"": ""AbbVie\u2019s U-turn shows its Shire deal was mostly about tax breaks, after all."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""height"": 360, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 360}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg"", ""height"": 614, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg"", ""height"": 1200, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie\u2019s U-Turn Shows Shire Deal Was Driven by Taxes"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-10-15T15:59:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520"", ""word_count"": 378, ""uri"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520""}"
2014-10-16,"{""abstract"": ""AbbVie walks away from its bid to acquire Shire. | JPMorgan cyberattack also hit its race website. | Fear returns to Wall Street."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/16/morning-agenda-abbvies-cold-feet/"", ""snippet"": ""AbbVie walks away from its bid to acquire Shire. | JPMorgan cyberattack also hit its race website. | Fear returns to Wall Street."", ""lead_paragraph"": ""The Obama administration\u2019s effort to curb maneuvers known as tax inversions has essentially killed the biggest corporate takeover of the year, DealBook\u2019s David Gelles writes. In the wake of new rules penalizing such inversions, AbbVie has walked away from its bid to acquire the Irish drug maker Shire for $54 billion. Late Wednesday, AbbVie, based in Illinois, said it would recommend that its shareholders vote against approving the deal in the event that it is put to a vote. In particular, AbbVie indicated that the new Treasury rules, which targeted the ability of companies that moved abroad to use overseas cash on a tax-free basis, had made the deal for Shire less financially attractive. The news sent shares of Shire tumbling in London."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: AbbVie\u2019s Cold Feet"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-10-16T12:20:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cd99f7dd-d01b-5ff8-85b9-a4bb6163bfc7"", ""word_count"": 1892, ""uri"": ""nyt://article/cd99f7dd-d01b-5ff8-85b9-a4bb6163bfc7""}"
2014-10-17,"{""abstract"": ""The deal would have united two of the biggest fertilizer producers in the world. It is the latest multinational deal to fall apart amid unsteady markets and questions about so-called inversion deals."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/17/yara-of-norway-and-cf-industries-call-off-merger-talks/"", ""snippet"": ""The deal would have united two of the biggest fertilizer producers in the world. It is the latest multinational deal to fall apart amid unsteady markets and questions about so-called inversion deals."", ""lead_paragraph"": ""LONDON \u2014 Two of the biggest fertilizer producers in the world on Friday ended their talks to merge, the latest multinational deal to fall apart amid unsteady markets and questions about so-called inversion deals."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Yara of Norway and CF Industries Call Off Merger Talks"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Fertilizer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Potash Corporation of Saskatchewan Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Yara International"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Chicago (Ill)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Norway"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-10-17T08:26:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9519cdf6-3308-55ad-afc4-b01af9d00512"", ""word_count"": 573, ""uri"": ""nyt://article/9519cdf6-3308-55ad-afc4-b01af9d00512""}"
2014-10-20,"{""abstract"": ""AbbVie will now pay Shire a $1.635 billion breakup fee \u2013 just weeks after the Treasury Department announced new rules taking aim at inversion deals."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/20/abbvie-and-shire-agree-to-terminate-their-deal/"", ""snippet"": ""AbbVie will now pay Shire a $1.635 billion breakup fee \u2013 just weeks after the Treasury Department announced new rules taking aim at inversion deals."", ""lead_paragraph"": ""AbbVie\u2018s deal for Shire is officially off."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""height"": 360, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 360}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg"", ""height"": 614, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg"", ""height"": 1200, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""After Tax Inversion Rules Change, AbbVie and Shire Agree to Terminate Their Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-10-20T22:05:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/65743165-5b7e-5c4b-aa6a-80844f54287a"", ""word_count"": 579, ""uri"": ""nyt://article/65743165-5b7e-5c4b-aa6a-80844f54287a""}"
2014-10-21,"{""abstract"": ""The truth hidden behind IBM\u2019s buybacks. | Private equity firms look to attract smaller investors. | Regulator warns on banks\u2019 bad behavior. | AbbVie and Shire agree to terminate their deal."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/21/morning-agenda-ibms-ugly-truth/"", ""snippet"": ""The truth hidden behind IBM\u2019s buybacks. | Private equity firms look to attract smaller investors. | Regulator warns on banks\u2019 bad behavior. | AbbVie and Shire agree to terminate their deal."", ""lead_paragraph"": ""Virginia M. Rometty, IBM\u2019s chief executive, has \u201ctalked a good game about focusing on \u2018shareholder value,\u2019\u201d Andrew Ross Sorkin writes in the DealBook Column. Even Warren E. Buffett, who has long held an aversion to technology companies, has invested in IBM. But these \u201cshareholder friendly\u201d maneuvers have been masking an ugly truth. \u201cIBM\u2019s success in recent years has been tied more to financial engineering than actual performance,\u201d Mr. Sorkin writes. This became apparent on Monday morning when the company announced its earnings, missing analysts\u2019 expectations by a wide margin. The stock fell more than 7 percent, to $169.10, by the end of the day, below the average price Mr. Buffett paid since he started buying the stock in 2011."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: IBM\u2019s Ugly Truth"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-10-21T11:42:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3256425f-7d69-5326-9ae2-667fa69661fb"", ""word_count"": 2399, ""uri"": ""nyt://article/3256425f-7d69-5326-9ae2-667fa69661fb""}"
2014-11-18,"{""abstract"": ""A pair of deals announced on Monday, worth $100 billion, brought the year\u2019s total for American companies to $1.5 trillion, the highest since 2000."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/17/mega-mergers-popular-again-on-wall-street/"", ""snippet"": ""A pair of deals announced on Monday, worth $100 billion, brought the year\u2019s total for American companies to $1.5 trillion, the highest since 2000."", ""lead_paragraph"": ""Stocks are surging, corporate executives are ambitious and debt is cheap. The result is one of the biggest booms ever in mergers and acquisitions."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/18/business/18mergers-graphic/18mergers-graphic-jumbo-v2.png"", ""height"": 381, ""width"": 592, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/18/business/18mergers-graphic/18mergers-graphic-superJumbo-v2.png"", ""height"": 381, ""width"": 592, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/18/business/18mergers-graphic/18mergers-graphic-thumbStandard-v3.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/18/business/18mergers-graphic/18mergers-graphic-thumbStandard-v3.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/18/business/18mergers-graphic/18mergers-graphic-thumbLarge-v3.png"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Mega-Mergers Popular Again on Wall Street"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Mega-Mergers Popular Again on Wall Street"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Banking and Financial Institutions"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Actavis PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2014-11-18T02:29:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a16008a0-df42-53fa-973a-0a58322cfcde"", ""word_count"": 1173, ""uri"": ""nyt://article/a16008a0-df42-53fa-973a-0a58322cfcde""}"
2014-12-19,"{""abstract"": ""Insurers are hoping that a new competitor to Gilead Sciences\u2019 drugs for the disease will drive down prices, though the new drug\u2019s price is higher than was hoped."", ""web_url"": ""https://www.nytimes.com/2014/12/20/business/abbvie-wins-approval-of-hepatitis-c-treatment.html"", ""snippet"": ""Insurers are hoping that a new competitor to Gilead Sciences\u2019 drugs for the disease will drive down prices, though the new drug\u2019s price is higher than was hoped."", ""lead_paragraph"": ""A new treatment for hepatitis C developed by AbbVie won approval from the Food and Drug Administration on Friday, setting the stage for a marketing battle with Gilead Sciences, whose two new drugs for the disease have drawn an outcry about the high cost of medicines."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Harvoni (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-12-19T22:02:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cbc82cf5-b737-5768-aaab-f09d4768b13e"", ""word_count"": 1059, ""uri"": ""nyt://article/cbc82cf5-b737-5768-aaab-f09d4768b13e""}"
2014-12-22,"{""abstract"": ""Express Scripts, the nation\u2019s largest manager of prescriptions, has negotiated a \u201csignificant discount\u201d for Viekira Pak, a new entrant to the expensive class of hepatitis C medications."", ""web_url"": ""https://www.nytimes.com/2014/12/22/business/pharmacy-deal-heralds-changed-landscape-for-hepatitis-drugs.html"", ""snippet"": ""Express Scripts, the nation\u2019s largest manager of prescriptions, has negotiated a \u201csignificant discount\u201d for Viekira Pak, a new entrant to the expensive class of hepatitis C medications."", ""lead_paragraph"": ""In a sign that price competition may take hold for hepatitis C drugs, the nation\u2019s largest manager of prescriptions will require all patients to use AbbVie\u2019s newly approved treatment rather than two widely used medicines from its rival Gilead Sciences. "", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/22/business/22-drug/22-drug-articleLarge.jpg"", ""height"": 385, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/22/business/22-drug/22-drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 385}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/22/business/22-drug/22-drug-jumbo.jpg"", ""height"": 657, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/22/business/22-drug/22-drug-superJumbo.jpg"", ""height"": 821, ""width"": 1279, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/22/business/22-drug/22-drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/22/business/22-drug/22-drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/22/business/22-drug/22-drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie Deal Heralds Changed Landscape for Hepatitis Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pharmacy Deal Heralds Changed Landscape for Hepatitis Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Harvoni (Drug)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-12-22T05:01:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/151e37a2-47c5-51fb-a64b-537ad7bc29cd"", ""word_count"": 877, ""uri"": ""nyt://article/151e37a2-47c5-51fb-a64b-537ad7bc29cd""}"
2015-01-06,"{""abstract"": ""The agreement partly offsets a similar pact between the pharmacy benefit manager Express Scripts and AbbVie, another maker of a costly hepatitis C drug."", ""web_url"": ""https://www.nytimes.com/2015/01/06/business/gilead-strikes-hepatitis-drug-deal-with-cvs-health.html"", ""snippet"": ""The agreement partly offsets a similar pact between the pharmacy benefit manager Express Scripts and AbbVie, another maker of a costly hepatitis C drug."", ""lead_paragraph"": ""Gilead Sciences struck back on Monday against its rival AbbVie in a budding marketing war over costly hepatitis C drugs, winning exclusive access to many patients whose prescriptions are managed by CVS Health."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Gilead Strikes Hepatitis Drug Deal With CVS Health"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""CVS Gives Gilead Exclusivity for Two Hepatitis Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CVS Caremark Corporation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hepatitis"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Harvoni (Drug)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-01-06T02:07:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fee5b257-e117-507e-98cb-1dc561497180"", ""word_count"": 435, ""uri"": ""nyt://article/fee5b257-e117-507e-98cb-1dc561497180""}"
2015-01-11,"{""abstract"": ""The Irish drug maker Shire is paying a premium for NPS Pharmaceuticals, which is based in New Jersey, as part of its effort to recover from its botched sale to AbbVie last year."", ""web_url"": ""https://dealbook.nytimes.com/2015/01/11/shire-to-buy-nps-pharmaceuticals-for-5-2-billion/"", ""snippet"": ""The Irish drug maker Shire is paying a premium for NPS Pharmaceuticals, which is based in New Jersey, as part of its effort to recover from its botched sale to AbbVie last year."", ""lead_paragraph"": ""The Irish drug maker Shire has agreed to acquire NPS Pharmaceuticals for $5.2 billion, a deal that will allow it to move on from its botched sale to AbbVie last year."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/12/business/12skymain1/12skymain1-articleLarge.jpg"", ""height"": 394, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/12/business/12skymain1/12skymain1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 394}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/12/business/12skymain1/12skymain1-jumbo.jpg"", ""height"": 673, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/12/business/12skymain1/12skymain1-superJumbo.jpg"", ""height"": 1346, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/12/business/12skymain1/12skymain1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/12/business/12skymain1/12skymain1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/12/business/12skymain1/12skymain1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Shire to Buy NPS Pharmaceuticals for $5.2 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Shire to Buy NPS Pharmaceuticals for $5.2 Billion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NPS Pharmaceuticals Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-01-11T18:27:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/584dd7a1-d55b-5852-a7b2-a5a30faddb52"", ""word_count"": 787, ""uri"": ""nyt://article/584dd7a1-d55b-5852-a7b2-a5a30faddb52""}"
2015-01-12,"{""abstract"": ""Shire is paying a 51 percent premium for NPS, and it is making a potentially risky deal ahead of an important regulatory ruling, Neil Unmack of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2015/01/12/shire-gambles-abbvie-break-up-fee-on-a-risky-deal/"", ""snippet"": ""Shire is paying a 51 percent premium for NPS, and it is making a potentially risky deal ahead of an important regulatory ruling, Neil Unmack of Reuters Breakingviews writes."", ""lead_paragraph"": ""Shire is gambling its AbbVie breakup fee on risky M.&A."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/11/business/dealbook/dbpix-shire-nps/dbpix-shire-nps-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Shire Gambles AbbVie Breakup Fee on a Risky Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ornskov, Flemming"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-01-12T17:00:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/072c1e07-d35c-54bb-ba8a-3b654dd86b54"", ""word_count"": 468, ""uri"": ""nyt://article/072c1e07-d35c-54bb-ba8a-3b654dd86b54""}"
2015-03-04,"{""abstract"": ""AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments."", ""web_url"": ""https://www.nytimes.com/2015/03/05/business/dealbook/abbvie-to-pay-21-billion-for-pharmacyclics-maker-of-a-best-selling-cancer-treatment.html"", ""snippet"": ""AbbVie announced that it has agreed to buy Pharmacyclics, a maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments."", ""lead_paragraph"": ""AbbVie announced late Wednesday that it had agreed to buy Pharmacyclics, maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments for the disease, for about $21 billion."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/05/business/dbpix-pharma/dbpix-pharma-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Promising Cancer Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""AbbVie to Pay $21 Billion for Pharmacyclics, Maker of a Best-Selling Cancer Treatment"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pharmacyclics, Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-03-04T23:02:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Andrew Pollack"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d9a1bd24-6821-5647-b2c4-070df97be473"", ""word_count"": 725, ""uri"": ""nyt://article/d9a1bd24-6821-5647-b2c4-070df97be473""}"
2015-03-05,"{""abstract"": ""With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson."", ""web_url"": ""https://www.nytimes.com/2015/03/06/business/dealbook/why-abbvie-may-have-overpaid.html"", ""snippet"": ""With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson."", ""lead_paragraph"": ""AbbVie\u2019s chief executive may have overpaid once again."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Why AbbVie May Have Overpaid for Cancer Drug Maker"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pharmacyclics, Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-03-05T20:23:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Dealbook"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0489cc36-72af-5e00-b03e-5a0be61145d0"", ""word_count"": 378, ""uri"": ""nyt://article/0489cc36-72af-5e00-b03e-5a0be61145d0""}"
2015-03-06,"{""abstract"": ""Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much."", ""web_url"": ""https://www.nytimes.com/2015/03/06/business/abbvie-wins-bidding-war-for-maker-of-cancer-drug-then-goes-on-defensive.html"", ""snippet"": ""Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much."", ""lead_paragraph"": ""Robert Duggan, according to his many websites, has played basketball with Pat Riley of the N.B.A., taught his children to surf by the time they were 3 and made fortunes starting and selling companies in fields as varied as cookies and robot surgery. He is the largest donor to the Church of Scientology."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie Wins Bidding War for Maker of Cancer Drug, Then Goes on Defensive"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""AbbVie Wins Bidding War, Then Goes on Defensive"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pharmacyclics, Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Duggan, Robert W"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-03-06T02:07:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fb1a05b3-3168-5577-9a96-dfacac79b169"", ""word_count"": 1225, ""uri"": ""nyt://article/fb1a05b3-3168-5577-9a96-dfacac79b169""}"
2015-04-28,"{""abstract"": ""It\u2019s estimated that about three million Americans have celiac disease. And even though a gluten-free diet can help alleviate symptoms, it\u2019s not a cure-all."", ""web_url"": ""https://www.nytimes.com/2015/04/29/business/celiac-diseases-prominence-has-drug-companies-racing-to-find-treatments.html"", ""snippet"": ""It\u2019s estimated that about three million Americans have celiac disease. And even though a gluten-free diet can help alleviate symptoms, it\u2019s not a cure-all."", ""lead_paragraph"": ""Like many people with a sensitivity to gluten, Kristen Sweet avoids the protein in wheat that can make her sick. But when she eats at a friend\u2019s house or a restaurant, she cannot be certain that the food is absolutely gluten-free."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""As Celiac and Gluten Sensitivities Gain Prominence, Drug Companies Race to Find Treatments"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Treating Celiac Disease"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Gluten"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Celiac Disease"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Avalon Ventures Limited"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alvine Pharmaceuticals Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sitari Pharmaceuticals Inc"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-04-28T20:52:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c8779569-9979-5645-ba8b-38beae0f58c8"", ""word_count"": 1426, ""uri"": ""nyt://article/c8779569-9979-5645-ba8b-38beae0f58c8""}"
2015-08-04,"{""abstract"": ""The deal has industrial logic as well as tax benefits. Shire shareholders, however, might have preferred being bought out to taking on a takeover."", ""web_url"": ""https://www.nytimes.com/2015/08/05/business/dealbook/shires-merger-machine-stumbles-on-baxalta-bid.html"", ""snippet"": ""The deal has industrial logic as well as tax benefits. Shire shareholders, however, might have preferred being bought out to taking on a takeover."", ""lead_paragraph"": ""Shire\u2019s merger machine has taken a gentle knock. Shire, the onetime Irish target for AbbVie, is planning a mega-deal of its own. Unlike the previous combination, Shire\u2019s $30 billion lunge for Baxalta carries a fair slug of industrial logic, as well as tax benefits. Its shareholders, though, still need some persuading."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Shire\u2019s Merger Machine Stumbles on Baxalta Bid"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-08-04T18:43:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/def5d5f5-4c62-59e1-8994-0f2cd5914566"", ""word_count"": 432, ""uri"": ""nyt://article/def5d5f5-4c62-59e1-8994-0f2cd5914566""}"
2015-09-16,"{""abstract"": ""Mr. Gosebruch, 42, who was promoted in March to co-head of North American mergers, has been one of the bank\u2019s top deal makers for the pharmaceutical industry."", ""web_url"": ""https://www.nytimes.com/2015/09/17/business/dealbook/henry-gosebruch-rising-star-at-jpmorgan-is-departing-for-abbvie.html"", ""snippet"": ""Mr. Gosebruch, 42, who was promoted in March to co-head of North American mergers, has been one of the bank\u2019s top deal makers for the pharmaceutical industry."", ""lead_paragraph"": ""One of JPMorgan Chase\u2019s two co-heads of North American mergers is leaving the firm to join a longtime client, only months after being promoted to the position."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-articleLarge.jpg"", ""height"": 769, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 769}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-jumbo.jpg"", ""height"": 1024, ""width"": 799, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-superJumbo.jpg"", ""height"": 2048, ""width"": 1598, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/09/17/business/17db-morgan-web1/17db-morgan-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Henry Gosebruch, Rising Star at JPMorgan, Is Departing for AbbVie"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Appointments and Executive Changes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gosebruch, Henry (1972- )"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-09-16T22:12:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ba7978fe-a9a4-585e-a19c-535e93a033fd"", ""word_count"": 250, ""uri"": ""nyt://article/ba7978fe-a9a4-585e-a19c-535e93a033fd""}"
2015-10-06,"{""abstract"": ""Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products."", ""web_url"": ""https://www.nytimes.com/2015/10/07/business/express-scripts-says-it-will-cover-2-new-cholesterol-drugs.html"", ""snippet"": ""Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products."", ""lead_paragraph"": ""The nation\u2019s largest manager of drug prescriptions said on Tuesday that it would pay for two drugs in a promising new class of cholesterol-lowering medicines, rather than choose one over the other in an effort to lower costs."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Express Scripts Says It Will Cover 2 New Cholesterol Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Express Scripts Will Cover 2 New Cholesterol Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Express Scripts Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Repatha (Drug)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Praluent (Drug)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cholesterol"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Regeneron Pharmaceuticals Inc"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-10-06T21:00:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1d43e58f-d265-5687-8309-22251685ed46"", ""word_count"": 772, ""uri"": ""nyt://article/1d43e58f-d265-5687-8309-22251685ed46""}"
2015-11-02,"{""abstract"": ""The transaction would be the latest in an acquisition spree by Shire since its tentative agreement to be bought by the drug maker AbbVie was terminated."", ""web_url"": ""https://www.nytimes.com/2015/11/03/business/dealbook/shire-dyax-corp-deal.html"", ""snippet"": ""The transaction would be the latest in an acquisition spree by Shire since its tentative agreement to be bought by the drug maker AbbVie was terminated."", ""lead_paragraph"": ""LONDON \u2014 The Irish drug maker Shire said on Monday that it had agreed to acquire the American biotechnology company Dyax Corporation in a deal that could be worth as much as $6.5 billion."", ""print_section"": ""B"", ""print_page"": ""11"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-superJumbo.jpg"", ""height"": 1366, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/03/business/db-shire-web1/db-shire-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Irish Drug Maker Shire Agrees to Buy Dyax in Deal Worth Up to $6.5 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Irish Drug Maker Shire Agrees to Buy Dyax in Deal Worth Up to $6.5 Billion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dyax Corporation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NPS Pharmaceuticals Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-11-02T13:54:11+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6ab5f1e2-ec04-5e3e-a10e-b9b43cdf3514"", ""word_count"": 455, ""uri"": ""nyt://article/6ab5f1e2-ec04-5e3e-a10e-b9b43cdf3514""}"
2016-04-28,"{""abstract"": ""AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment."", ""web_url"": ""https://www.nytimes.com/2016/04/29/business/dealbook/abbvie-to-buy-cancer-treatment-start-up.html"", ""snippet"": ""AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 In Silicon Valley, being a unicorn is no guarantee of financial success. But an eight-year-old drug maker focused on novel cancer treatments has landed itself and its investors a windfall by selling itself to a bigger competitor."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-ABBVIE/29DB-ABBVIE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie to Buy Cancer Treatment Start-Up"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Stemcentrx Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stem Cells"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2016-04-28T13:35:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Andrew Pollack"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/565ca511-a392-5f06-a704-32217f442ae9"", ""word_count"": 989, ""uri"": ""nyt://article/565ca511-a392-5f06-a704-32217f442ae9""}"
2016-04-29,"{""abstract"": ""Deals worth over $40 billion were announced Thursday as companies teamed up to become leading providers and gain clout to negotiate with hospitals and insurers."", ""web_url"": ""https://www.nytimes.com/2016/04/29/business/dealbook/health-care-companies-see-scale-as-the-only-way-to-compete.html"", ""snippet"": ""Deals worth over $40 billion were announced Thursday as companies teamed up to become leading providers and gain clout to negotiate with hospitals and insurers."", ""lead_paragraph"": ""A spate of deals on Thursday showed that health care companies are convinced, regardless of tax benefits, that bigger is not only better, it is necessary."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-articleLarge.jpg"", ""height"": 641, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 641}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-jumbo.jpg"", ""height"": 1024, ""width"": 959, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-superJumbo.jpg"", ""height"": 1842, ""width"": 1724, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/29/business/29DB-CARE/29DB-CARE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Health Care Companies See Scale as the Only Way to Compete"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Flurry of Deals as Health Companies Bulk Up"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""St Jude Medical Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-04-29T00:59:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dfd62666-a9d4-5720-83f8-7e94af6a81c9"", ""word_count"": 830, ""uri"": ""nyt://article/dfd62666-a9d4-5720-83f8-7e94af6a81c9""}"
2016-07-15,"{""abstract"": ""Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow."", ""web_url"": ""https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html"", ""snippet"": ""Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow."", ""lead_paragraph"": ""The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg"", ""height"": 851, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 851}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-jumbo.jpg"", ""height"": 1024, ""width"": 723, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-superJumbo.jpg"", ""height"": 2048, ""width"": 1445, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Patents Aim to Delay Generics of Biologics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Patient Protection and Affordable Care Act (2010)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-07-15T23:45:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/781638b3-86bb-550c-94a0-d9f71db0317e"", ""word_count"": 1057, ""uri"": ""nyt://article/781638b3-86bb-550c-94a0-d9f71db0317e""}"
